2016 Fiscal Year Final Research Report
Nrf2 activator attenuates brain ischemia-reperfusion injury.
| Project/Area Number |
15K19960
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Hyogo Medical University (2016)
Gifu University (2015) |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Hara Hideaki 岐阜薬科大学, 薬効解析学, 教授
Yoshimura Shinichi 兵庫医科大学, 医学部, 主任教授
Iwama Toru 岐阜大学, 大学院医学系研究科 脳神経外科, 教授
Yamauchi Keita 岐阜大学, 大学院医学系研究科 脳神経外科
Egashira Yusuke 岐阜大学, 大学院医学系研究科 脳神経外科
Imai Takahiko 岐阜薬科大学, 薬効解析学
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | Nrf2 / 脳虚血再灌流障害 / 脳血液関門 / 酸化ストレス |
|---|
| Outline of Final Research Achievements |
Bardoxylone methyl（BARD）and novel Nrf2 activator, RS-9 decreased cerebral infarction and improve neurological findings due to ischemia-reperfusion injury. In addition, BARD decreased hemorrhagic infarction and improve neurological findings under warfarin administration. BARD also attenuates hyper-permeability of blood brain barrier and ameliorates the injury of vascular endothelial cells and pericytes.
These results demonstrated the neuroprotective effects of Nrf2 activator and protection of blood brain barrier.
|
| Free Research Field |
脳虚血、脳保護療法
|
